PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 301–400 of 1,000
Solís, M. C., Gil-Torralvo, A., Castilla, M. Á., Dominguez-Cejudo, M. A., Falcón, A., Benavent, M., Molina‐Pinelo, S., Ruíz-Borrego, M., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108488 · Cited by 87
Therapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 97
Haricharan, S., Punturi, N. B., Singh, P., Holloway, K. R., Anurag, M., Schmelz, J. L., Schmidt, C., Lei, J. T., Suman, V. J., Hunt, K. K., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1179 · Cited by 78
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Xie, Z., Hou, S., Yang, X., Duan, Y., Han, J., Wang, Q., & Liao, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02190 · Cited by 80
Reddy, M. V. R., Akula, B., Cosenza, S. C., Divakar, S. K. A., Mallireddigari, M. R., Pallela, V. R., Billa, V. K., Subbaiah, D. R. C. V., Bharathi, E. V., Carpio, R. V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401073p · Cited by 80
Patel, P. M., Tsiperson, V., Gottesman, S. R. S., Somma, J., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0602 · Cited by 77
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 82
Chiron, D., Martin, P., Di Liberto, M., Huang, X., Ely, S., Lannutti, B. J., Leonard, J. P., Mason, C. E., & Chen-Kiang, S. (2013) · Cell Cycle · doi:10.4161/cc.24928 · Cited by 71
Varella, L., Eziokwu, A. S., Jia, X., Kruse, M. L., Moore, H. C. F., Budd, G. T., Abraham, J., & Montero, A. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05176-1 · Cited by 77
Petroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen‐Kiang, S., Formenti, S. C., & Galluzzi, L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3871 · Cited by 73
The Renaissance of Cyclin Dependent Kinase Inhibitors
Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 76
the 11q13‐q14 amplicon: Clinicopathological correlations and potential drivers
Wilkerson, P. M., & Reis-Filho, J. S. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22037 · Cited by 73
Wainberg, Z. A., Anghel, A., Rogers, A. M., Desai, A. J., Kalous, O., Conklin, D. F., Ayala, R., O’Brien, N. A., Quadt, C., Akimov, M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0507 · Cited by 70
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 69
Boers, J., Venema, C. M., de Vries, E. F. J., Glaudemans, A. W. J. M., Kwee, T. C., Schuuring, E. M. D., Martens, J. W. M., Elias, S. G., Hospers, G. A. P., & Schroder, C. P. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.024 · Cited by 75
Lu, J. M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0194-5 · Cited by 73
Hanaford, A. R., Archer, T. C., Price, A. C., Kahlert, U. D., Maciaczyk, J., Nikkhah, G., Kim, J. W., Ehrenberger, T., Clemons, P. A., Dančík, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3011 · Cited by 80
Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 74
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
Aggelis, V., & Johnston, S. R. D. (2019) · Drugs · doi:10.1007/s40265-019-01208-8 · Cited by 78
MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
Chen, X., Burkhardt, D. B., Hartman, A. A., Hu, X., Eastman, A. E., Sun, C., Wang, X., Zhong, M., Krishnaswamy, S., & Guo, S. (2019) · Nature Communications · doi:10.1038/s41467-019-13666-5 · Cited by 58
Severson, T., Peeters, J. K., Majewski, I. J., Michaut, M., Bosma, A. R., Schouten, P. C., Chin, S., Pereira, B., Goldgraben, M. A., Bismeijer, T., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.011 · Cited by 72
Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 71
Hortobágyi, G. N. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1050-7 · Cited by 69
Emerging therapies for breast cancer
Hu, X., Huang, W., & Fan, M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0466-3 · Cited by 67
Palbociclib-induced autophagy and senescence in gastric cancer cells
Valenzuela, C. A., Vargas, L., Martinez, V., Bravo, S., & Brown, N. E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.031 · Cited by 67
Physiologically Based Pharmacokinetic Modeling of Palbociclib
Yu, Y., Loi, C., Hoffman, J., & Wang, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.792 · Cited by 68
van Ommen‐Nijhof, A., Konings, I. R. H. M., van Zeijl, C. J. J., Groot, C. A. U., van der Noort, V., Jager, A., & Sonke, G. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4978-1 · Cited by 70
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
Márquez‐Garbán, D. C., Deng, G., Comin-Anduix, B., Garcia, A. J., Xing, Y., Chen, H., Cheung-Lau, G. C., Hamilton, N. M., Jung, M. E., & Pietras, R. J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105415 · Cited by 73
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
“…this combination is particularly ef fi cacious against CT26 colon carcinoma cells (108 – 110), which interestingly harbor a Cdkn2a deletion and expresses functional RB (143, 144), likely rendering it highly sensitive to the tumor-intrinsic immunomodulatory effects of CDK4/6 inhibition.”
BackgroundPapadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 78
Gogolin, S., Ehemann, V., Becker, G., Brueckner, L. M., Dreidax, D., Bannert, S., Nolte, I. J. A., Savelyeva, L., Bell, E., & Westermann, F. (2013) · Cell Cycle · doi:10.4161/cc.24091 · Cited by 76
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Atefi, M., Titz, B., Avramis, E., Ng, C., Wong, D. J., Lassen, A., Cerniglia, M., Escuin-Ordinas, H., Foulad, D., Comin-Anduix, B., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0293-5 · Cited by 64
Cyclin D degradation by E3 ligases in cancer progression and treatment
Qie, S., & Diehl, J. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.012 · Cited by 72
The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, C. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0651-4 · Cited by 68
Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis
Imamura, T., Yamamoto‐Ibusuki, M., Sueta, A., Kubo, T., Irie, A., Kikuchi, K., Kariu, T., & Iwase, H. (2015) · Breast Cancer · doi:10.1007/s12282-015-0654-3 · Cited by 76
Hurvitz, S. A., Kalous, O., Conklin, D. F., Desai, A. J., Dering, J., Anderson, L. A., O’Brien, N. A., Kolarova, T. R., Finn, R. S., Linnartz, R., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3282-x · Cited by 74
Liu, C., Lau, K.-Y., Hsu, C., Chen, J.-L., Lee, C.-H., Huang, T., Chen, Y., Huang, C.-T., Lin, P., & Tseng, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189007 · Cited by 71
Arnedos, M., Bayar, M. A., Cheaib, B., Scott, V., Bouakka, I., Valent, A., Adam, J., Leroux-Kozal, V., Marty, V., Rapinat, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy202 · Cited by 64
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 71
Collins, J. M., Nordstrom, B. L., McLaurin, K. K., Dalvi, T. B., McCutcheon, S., Bennett, J. C., Murphy, B. R., Singhal, P. K., McCrea, C., Shinde, R., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00162-4 · Cited by 72
Targeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 80
Wiedemeyer, W. R., Beach, J. A., & Karlan, B. Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00034 · Cited by 71
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 65
Recent Advances and Perspectives in Cancer Drug Design
Magalhães, L. G., Ferreira, L. L. G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170823 · Cited by 80
Identifying Cancers Impacted by CDK8/19
Roninson, I. B., Győrffy, B., Mack, Z. T., Shtil, A. A., Shtutman, M. S., Chen, M., & Broude, E. V. (2019) · Cells · doi:10.3390/cells8080821 · Cited by 66
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
Pérez, M., Muñoz-Galván, S., Jiménez-García, M. P., Marín, J., & Carnero, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5829 · Cited by 71
Swiercz, R., Mo, M., Khare, P., Schneider, Z., Ober, R. J., & Ward, E. S. (2016) · Oncotarget · doi:10.18632/oncotarget.13869 · Cited by 67
Battisti, N. M. L., de Glas, N. A., Sedrak, M. S., Loh, K. P., Liposits, G. I., Soto‐Pérez‐de‐Celis, E., Krok‐Schoen, J. L., Menjak, I. B., & Ring, A. E. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918809610 · Cited by 65
Baba, R. E., & Herbein, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730765 · Cited by 69
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1
Sathe, A., Koshy, N. R., Schmid, S. C., Thalgott, M. K., Schwarzenböck, S. M., Krause, B. J., Holm, P. S., Gschwend, J. E., Retz, M. M., & Nawroth, R. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.08.082 · Cited by 84
CDK4/6 inhibition in early and metastatic breast cancer: A review
de Groot, A. F., Kuijpers, C. C. H. J., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.003 · Cited by 73
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Roberts, P. J., Kumarasamy, V. M., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1161 · Cited by 66
Prat, A., Brasó‐Maristany, F., Martínez‐Sáez, O., Sanfeliu, E., Xia, Y., Bellet, M., Galván, P., Martínez, D., Pascual, T., Marín‐Aguilera, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36801-9 · Cited by 65
Garon, E. B., Pietras, R. J., Finn, R. S., Kamranpour, N., Pitts, S. L., Márquez‐Garbán, D. C., Desai, A. J., Dering, J., Hosmer, W., von Euw, E. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827d525c · Cited by 60
Breast cancer genomes — form and function
Korkola, J. E., & Gray, J. W. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.005 · Cited by 85
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Tarrado‐Castellarnau, M., de Atauri, P., Tarragó‐Celada, J., Perarnau, J., Yuneva, M. O., Thomson, T. M., & Cascante, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167321 · Cited by 65
Novel Molecular Markers for Breast Cancer
Inoue, K., & Fry, E. A. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s38394 · Cited by 70
Choupani, E., Gomari, M. M., Zanganeh, S., Nasseri, S., Haji-Allahverdipoor, K., Rostami, N., Hernandez, Y., Najafi, S., Saraygord‐Afshari, N., & Hosseini, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000665 · Cited by 64
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 73
New approaches for improving outcomes in breast cancer in Europe
Leo, A. D., Curigliano, G., Dieras, V. C., Malorni, L., Sotiriou, C. P., Swanton, C., Thompson, A. M., Tutt, A. N. J., & Piccart, M. J. (2015) · The Breast · doi:10.1016/j.breast.2015.03.001 · Cited by 67
E2F Activators Signal and Maintain Centrosome Amplification in Breast Cancer Cells
Lee, M.-Y., Moreno, C. S., & Saavedra, H. I. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01688-13 · Cited by 64
Chen, L., & Pan, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13836 · Cited by 60
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Menon, M., Elliott, R., Bowers, L., Balan, N., Rafiq, R., Costa-Cabral, S., Munkonge, F., Trinidade, I., Porter, R., Campbell, A. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36447-4 · Cited by 60
Sutherland, R. L., & Musgrove, E. A. (2009) · Breast Cancer Research · doi:10.1186/bcr2454 · Cited by 60
Li, Y., Wang, P., Li, X. X., Yu, C. Y., Yang, H. J., Zhou, J., Xue, W., Tan, J., & Zhu, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165737 · Cited by 64
Bone Density and Dental External Apical Root Resorption
Iglesias‐Linares, A., Morford, L. A., & Hartsfield, J. K. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0340-1 · Cited by 78
Rohde, M., Bonn, B. R., Zimmermann, M., Lange, J., Möricke, A., Klapper, W., Oschlies, I., Szczepanowski, M., Nagel, I., Schrappe, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.156885 · Cited by 61
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, S., Sami, A., Manna, M., Pauls, M., & Ahmed, S. (2021) · Current Oncology · doi:10.3390/curroncol28030168 · Cited by 67
Progress with palbociclib in breast cancer: latest evidence and clinical considerations
Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 69
Warth, B., Raffeiner, P., Granados, A., Huan, T., Fang, M., Forsberg, E. M., Benton, H. P., Goetz, L. H., Johnson, C. H., & Siuzdak, G. E. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2017.12.010 · Cited by 66
To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 62
Who guards the guardian? Mechanisms that restrain APC/C during the cell cycle
Kernan, J. L., Bonacci, T., & Emanuele, M. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.09.011 · Cited by 70
Cancer takes many paths through G1/S
Knudsen, E. S., Witkiewicz, A. K., & Rubin, S. M. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.10.007 · Cited by 63
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Kazansky, Y., Cameron, D., Mueller, H. S., Demarest, P., Zaffaroni, N., Arrighetti, N., Zuco, V., Kuwahara, Y., Somwar, R., Ladanyi, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0110 · Cited by 61
Tessoulin, B., Moreau‐Aubry, A., Descamps, G., Gomez‐Bougie, P., Maïga, S., Gaignard, A., Chiron, D., Ménoret, E., Gouill, S. L., Moreau, P., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0679-0 · Cited by 62
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
Witkiewicz, A. K., Borja, N. A., Franco, J., Brody, J. R., Yeo, C. J., Mansour, J., Choti, M. A., McCue, P., & Knudsen, E. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3819 · Cited by 56
Current Trends in the Treatment of HR+/HER2+ Breast Cancer
Kay, C., Martínez-Pérez, C., Meehan, J., Gray, M., Webber, V. L., Dixon, J. M., & Turnbull, A. (2021) · Future Oncology · doi:10.2217/fon-2020-0504 · Cited by 65
Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
Chow, L. W., Morita, S., Chow, C. Y. C., Ng, W.-K., & Toi, M. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0396 · Cited by 57
Miller, T. W., Traphagen, N. A., Li, J., Lewis, L. D., Lopes, B., Asthagiri, A. R., Loomba, J. J., Jong, J. D., Schiff, D., Patel, S. H., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03258-0 · Cited by 56
Robinson, A. M., Rathore, R., Redlich, N. J., Adkins, D. R., VanArsdale, T. L., Tine, B. A. V., & Michel, L. S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2098-8 · Cited by 57
Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects
Gross, S. M., Mohammadi, F., Sanchez-Aguila, C., Zhan, P. J., Liby, T. A., Dane, M. A., Meyer, A. S., & Heiser, L. M. (2023) · Nature Communications · doi:10.1038/s41467-023-39122-z · Cited by 61
Lam, F., Abbas, A. Y., Shao, H., Teo, T., Adams, J., Li, P., Bradshaw, T. D., Fischer, P. M., Walsby, E. J., Pepper, C. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2296 · Cited by 60
Bonuccelli, G., Peiris‐Pagès, M., Ózsvári, B., Martinez‐Outschoorn, U., Sotgia, F., & Lisanti, M. P. (2016) · Oncotarget · doi:10.18632/oncotarget.14196 · Cited by 58
Zañudo, J. G. T., Scaltriti, M., & Albert, R. (2017) · Cancer Convergence · doi:10.1186/s41236-017-0007-6 · Cited by 64
Canu, G., Athanasiadis, E. I., Grandy, R. A., Garcia‐Bernardo, J., Strzelecka, P. M., Vallier, L., Ortmann, D., & Cvejic, A. (2020) · Genome biology · doi:10.1186/s13059-020-02058-4 · Cited by 50
Francis, A. M., Alexander, A., Liu, Y., Vijayaraghavan, S., Low, K. H., Yang, D., Bui, T., Somaiah, N., Ravi, V., Keyomarsi, K., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0040 · Cited by 54
Lenin, S., Ponthier, E., Scheer, K. G., Yeo, E. C. F., Tea, M. N., Ebert, L. M., Mansilla, M. O., Poonnoose, S. I., Baumgartner, U., Day, B. W., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094322 · Cited by 59
PARP14 regulates cyclin D1 expression to promote cell-cycle progression
O’Connor, M. J., Thakar, T., Nicolae, C. M., & Moldovan, G. (2021) · Oncogene · doi:10.1038/s41388-021-01881-8 · Cited by 62
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 63
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 70
Witt, B. L., & Tollefsbol, T. O. (2023) · Life · doi:10.3390/life13122311 · Cited by 73
Ismail, A., Bandla, S., Reveiller, M., Toia, L., Zhou, Z., Gooding, W. E., Kalatskaya, I., Stein, L., D'Souza, M., Litle, V. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0244 · Cited by 54
Zagorac, I., Fernandez-Gaitero, S., Penning, R., Post, H., Bueno, M. J., Mouron, S. A., Manso, L., Morente, M. M., Alonso, S. R., Serra, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05742-z · Cited by 62
Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4
Jia, W., Zhao, X., Zhao, L., Yan, H., Li, J., Yang, H., Huang, G., & Liu, J. (2018) · Oncogene · doi:10.1038/s41388-017-0072-4 · Cited by 58
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 60
Twenty-gene-based prognostic model predicts lung adenocarcinoma survival
Zhao, K., Li, Z., & Tian, H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s158638 · Cited by 54
FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular Modelling
Shafiq, M. I., Steinbrecher, T. B., & Schmid, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042612 · Cited by 54
Cello, F. D., Cope, L., Li, H., Jeschke, J., Wang, W., Baylin, S. B., & Zahnow, C. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068630 · Cited by 55
Kümler, I., Knoop, A. S., Jessing, C., Ejlertsen, B., & Nielsen, D. L. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000062 · Cited by 57
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.